

COVID-19 Monitor

COVID-19 cases, variants, vaccines, hospitalisations and deaths 11 November 2021

Table 1: NSW key indicators as at 7 November 2021*

Key indicators	Date: 7 Nov (change from: 31 Oct)
Average daily COVID-19 locally acquired cases, week to 7 Nov (previous week)	227 (-6)
Growth factor for locally acquired cases	1.00
Average daily COVID-19 deaths, week to 7 Nov (previous week)	4 (+1)
COVID-19 patients under the care of NSW Health, as at 7 Nov (previous week)	2,768 (+358)**
COVID-19 patients in hospital, as at 7 Nov (previous week)	263 (-85)
Percentage who were unvaccinated	62.3%
Percentage who were fully vaccinated	21.3%
COVID-19 patients in intensive care units (ICUs), as at 7 Nov (previous week)	47 (-29)
Percentage who were unvaccinated	79.2%
Percentage who were fully vaccinated	14.6%
Percentage of total ICU beds with COVID-19 patients (previous week)	9.6% (-6.0%)
Rates per million	
Average daily COVID-19 locally acquired cases, week to 7 Nov (previous week)	27.0 (-1)
COVID-19 under the care of NSW Health, as at 7 Nov	328.9
COVID-19 patients in hospital, as at 7 Nov	31.3
Hospital rate among unvaccinated / fully vaccinated 12+ population	326.0 / 9.4
COVID-19 patients in ICU, as at 7 Nov	5.6
ICU rate among unvaccinated / fully vaccinated 12+ population	85.6 / 1.3
COVID-19 vaccination, as at 7 Nov	
Percentage of eligible population (aged 12+) fully vaccinated	87.8%
Percentage of total population fully vaccinated	74.4%

*See [NSW key indicators: notes and sources](#) at the end of this document. **The increase in patients under the care of NSW Health over the last week is caused by a sudden increase in community clinic numbers, due to the allocation of previously unregistered cases

International reflections

- The [rollout of the booster vaccine in the UK](#) has been slower than initial vaccinations, with concerns that it may not be fast enough to avoid a winter crisis.¹
- The [US](#) began vaccinating children 5-11 years old on 3 November 2021.²
- In [Australia](#), booster shots were available from 8 November 2021.³
- The UK authorised the use of antiviral molnupiravir for treatment of mild to moderate COVID-19.¹
- Australia is expecting 500,000 courses of Pfizer's oral antiviral, [Paxlovid](#), which was reported to [reduce risk of hospitalisation or death by 89%](#) compared with placebo.^{1, 5, 6}
- Israel is seeing the impact of booster roll out; Japan has low levels of cases and clinically significant infections.

Table 2: Summary of public health, healthcare and vaccination measures (select countries, Canadian provinces and NSW) as at 8 November 2021*


	7-day average confirmed cases	7-day average confirmed cases (per million)	7-day average deaths (per million)	% total population fully vaccinated	COVID-19 patients in hospital	COVID-19 patients in hospital (per million)	COVID-19 patients in ICU	COVID-19 patients in ICU (per million)
NSW	227	27.0	0.4	74.4%	263	31.3	47	5.6
Australia	1,386	53.8	0.5	67.0%	835	32.4	140	5.4
Belgium	11,169	960.1	2.5	73.8%	1,511	129.9	276	23.7
Canada	2372	62.3	0.6	74.8%	1,767	46.4	534	14.0
Ontario	468	31.6	0.3	74.9%	244	16.5	134	9.0
Quebec	558	64.8	0.4	76.2%	219	25.5	45	5.2
Denmark	2,306	396.7	0.7	76.0%	233	40.1	24	4.1
Israel	935	100.7	0.3	61.8%	226	25.7	121	13.8
Japan	194	1.5	0.0	74.1%	2,023	16.0	99	0.8
Portugal	998	98.1	0.7	87.4%	335	32.9	59	5.8
Singapore	2,851	522.8	2.4	86.2%	1,700	288.3	140	23.7
United Kingdom	34,121	500.3	2.5	67.2%	9,160	134.3	1,034	15.2
United States	73,235	220.0	3.5	57.2%	39,884	119.8	11,126	33.4

*Please see [Summary of public health: notes and sources](#) at the end of this document.

COVID-19 confirmed cases

Figure 1 shows the daily rate per million population (rolling seven-day average) of confirmed COVID-19 cases in NSW, Australia, United Kingdom, United States, Canada, Israel, Portugal and Denmark, from March 2020 to November 2021.

Figure 1: Daily rates of COVID-19 cases (select countries and NSW), March 2020 – November 2021




Note: Limited testing and delayed reporting likely result in underestimation of the actual number of confirmed cases.

Source: Data for the selected countries sourced from [Our World in Data](#).⁷ Data for NSW sourced from NSW Health via Notifiable Conditions Information Management System.⁸ Both accessed 9 November 2021.

COVID-19 mortality rates

Figure 2 shows the daily (rolling seven-day average) mortality rate per million population in NSW, Australia, United Kingdom, United States, Canada, Israel, Portugal and Denmark, from May to November 2021.

Figure 2: Daily mortality rates (select countries and NSW), May – November 2021



Note: Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.

Source: Data for the selected countries sourced from [Our World in Data](#).⁷ Data for NSW sourced from NSW Health via the Notifiable Conditions Information Management System.⁸ Both accessed 9 November 2021.

COVID-19 cases, testing, variants, vaccines, hospitalisations and deaths*

The following graphs (figures 3-8) show COVID-19 cases and vaccination rates; hospitalisation and death rates; and the variant distribution for NSW, Australia, United Kingdom, United States, Canada and Israel.

Series a: COVID-19 cases and vaccinations

The graphs in series 'a' show COVID-19 cases and vaccination rates for NSW and each of these countries from March 2020 to November 2021. They include:

- the daily rate per million population (rolling seven-day average) of confirmed COVID-19 cases
- the cumulative number of people who have received at least one vaccine dose (per 100 population)
- the cumulative number of people fully vaccinated (per 100 population).

These graphs should be interpreted with caution as there are other factors that may influence the number of cases in addition to vaccination rates, including the level of social restrictions.

The cumulative number of people vaccinated per hundred population (at least one dose or fully vaccinated) is based on the full population (all ages) for all locations and countries, including NSW, to enable accurate comparability. The number of people fully vaccinated in Australia is only available from late May 2021 onwards.

Note, there is variation in both 'x' axis and 'y' axis scales and some gaps in time series across these graphs due to missing data.

Series b: COVID-19 hospitalisation and death rates

The graphs in series 'b' show COVID-19 hospitalisation and death rates for NSW and each of these countries. Specifically, they show the daily number of hospitalised patients (per million population) and the daily number of new deaths (rolling seven-day average and per million population), from March 2020 to November 2021.

Note, there is variation in both 'x' axis and 'y' axis scales and some gaps in time series across these graphs due to missing data.

Series c: COVID-19 variant distribution

The stacked area graphs in series 'c' show the COVID-19 variant distribution for each of these countries. Specifically, they show COVID-19 variant distribution for cases sequenced, and the percentage of total COVID-19 cases sequenced, from May 2021 to November 2021.

For most countries, weekly counts are shown; however, only monthly counts were available for Canada. No information on variants is available for NSW.

Note, there is variation in both 'x' axis and 'y' axis scales and some gaps in time series across these graphs due to missing data.

**Please see further [COVID-19 cases: notes and sources](#) at the end of this document.*

NSW

Figure 3a: COVID-19 cases and vaccinations, NSW, March 2020 – November 2021





Figure 3b: COVID-19 hospitalisation and mortality rates, NSW, March 2020 – November 2021



In brief documents are not an exhaustive list of publications but aim to provide an overview of what is already known about a specific topic. This brief has not been peer-reviewed and should not be a substitute for individual clinical judgement, nor is it an endorsed position of NSW Health.

Australia

Figure 4a: COVID-19 cases and vaccinations, Australia, March 2020 – November 2021




Figure 4b: COVID-19 hospitalisation and mortality rates, Australia, March 2020 – November 2021





Figure 4c: COVID-19 variant distribution for sample of cases that have been sequenced, Australia, May – November 2021



In brief documents are not an exhaustive list of publications but aim to provide an overview of what is already known about a specific topic. This brief has not been peer-reviewed and should not be a substitute for individual clinical judgement, nor is it an endorsed position of NSW Health.

United Kingdom

Figure 5a: COVID-19 cases and vaccinations, United Kingdom, March 2020 – November 2021




Figure 5b: COVID-19 hospitalisation and mortality rates, United Kingdom, March 2020 – November 2021





Figure 5c: COVID-19 variant distribution for sample of cases that have been sequenced, United Kingdom, May – November 2021



United States

Figure 6a: COVID-19 cases and vaccinations, United States, March 2020 – November 2021




Figure 6b: COVID-19 hospitalisation and mortality rates, United States, March 2020 – November 2021





Figure 6c: COVID-19 variant distribution for a sample of cases that have been sequenced, United States, May – November 2021



Canada

Figure 7a: COVID-19 cases and vaccinations, Canada, March 2020 – November 2021




Figure 7b: COVID-19 hospitalisation and mortality rates, Canada, March 2020 – November 2021





Figure 7c: COVID-19 variant distribution for a sample of cases that have been sequenced, Canada, May – November 2021



Israel

Figure 8a: COVID-19 cases and vaccinations, Israel, March 2020 – November 2021




Figure 8b: COVID-19 hospitalisation and mortality rates, Israel, March 2020 – November 2021





Figure 8c: COVID-19 variant distribution for a sample of cases that have been sequenced, Israel, May – November 2021



NSW key indicators

Notes

- Data is presented for all indicators as at 7 November 2021 (previous week, 31 October 2021), data accessed on 9 November 2021.
- Average daily locally acquired cases and average daily deaths are based on the seven days to 7 November 2021 (previous week, seven days to 31 October 2021).
- For any given day, the growth factor for locally acquired cases is a ratio of cases notified in the seven days ending that day, to the cases notified in the seven days ending the day before.
- COVID-19 patients under the care of NSW Health include patients on the ward, ICUs, hospital in the home, out of hospital care and community clinics. Patients in hospital include cases on the ward and in ICUs.
- Estimated per million population rates calculated using population estimates at 30 June 2021, based on the Australian Bureau of Statistics estimated resident population and population projections based on data from the NSW Department of Planning, Industry and Environment.⁹ Elsewhere in this document (in the figures), 2019 population figures are used in line with international data available.
- Estimates for the full population and 12+ population figures used in calculating per million population rates for vaccination are drawn from NSW Health via the Australian Government Department of Health Australian Immunisation Register.¹⁰
- The rate of hospitalisation and ICU admission (per million) among the unvaccinated population is calculated as the number of unvaccinated COVID-19 cases in hospital against the estimated total number of the unvaccinated population. The rate of hospitalisation and ICU admission (per million) among the vaccinated population is calculated as the number of COVID-19 cases in hospital who have received at least two doses of vaccination, against the estimated total number of the fully vaccinated population. Rolling seven-day average was applied. Rates were age-standardised to NSW 2021 population estimates.

Sources

- New cases for NSW sourced from NSW Health via Notifiable Conditions Information Management System; accessed 9 November 2021.⁸
- Vaccination data sourced from NSW Health via the Australian Government Department of Health Australian Immunisation Register; accessed 9 November 2021.¹⁰
- Hospital capacity, admissions and proportion of vaccinated cases data is sourced from NSW Health via the Patient Flow Portal and is taken from a 7pm snapshot, 7 November 2021; accessed 9 November 2021.¹¹

Summary of public health, healthcare and vaccination measures (select countries and NSW)

Notes

- For the selected countries and Canadian provinces, data is presented for 8 November 2021. If unavailable, the latest available data is shown. For NSW, data is presented for 7 November 2021.

- Average daily confirmed cases and average daily deaths are based on a seven-day average.
- Proportions for the fully vaccinated are based on the full population. Population figures to calculate proportion covered for NSW are drawn from NSW Health via the Australian Government Department of Health Australian Immunisation Register.¹⁰
- For NSW, estimated per million population rates for all indicators other than vaccination are calculated using population estimates at 30 June 2021 based on the Australian Bureau of Statistics estimated resident population and population projections based on data from the NSW Department of Planning, Industry and Environment.⁹ Elsewhere in this document (in the figures), 2019 population figures are used in line with international data available.
- Patients in hospital include both cases on the ward and in ICUs. For Japan, patients in hospital numbers also include those receiving care at a dedicated facility or receiving treatment at home. Therefore, numbers are not directly comparable to other locations. For Ontario and Quebec, patients in hospital may be lower than patients in ICU, as the in-hospital numbers only include people still testing positive for COVID-19, while patients in ICU also include those who are in ICU due to COVID-19 but have since tested negative.
- Cell colouring has been applied according to the following criteria:
 - For 7-day average cases per million, patients in hospital per million and patients in ICU per million, highest three rates are highlighted in red, lowest three rates highlighted in green
 - For 7-day average deaths per million, highest three rates are highlighted in red
 - For percentage of total population fully vaccinated, percentages greater than or equal to 75% are highlighted in green.

Sources

- New cases for selected countries sourced from [Our World in Data](#).⁷ New cases for NSW sourced from NSW Health via the Notifiable Conditions Information Management System.⁸ New cases for Ontario and Quebec sourced from [COVID-19 Tracker Canada](#).¹² All accessed 9 November 2021.
- COVID-19 deaths for selected countries sourced from [Our World in Data](#).⁷ COVID-19 deaths for NSW sourced from NSW Health via the Notifiable Conditions Information Management System.⁸ COVID-19 deaths for Ontario and Quebec sourced from [COVID-19 Tracker Canada](#).¹² All accessed 9 November 2021.
- Vaccination data for selected countries sourced from [Our World in Data](#).⁷ Vaccination data for NSW sourced from NSW Health via the Australian Government Department of Health Australian Immunisation Register.¹⁰ Vaccination data for Ontario and Quebec sourced from [COVID-19 Tracker Canada](#).¹² All accessed 9 November 2021.
- Data on the number of COVID-19 patients in hospital and ICUs were sourced on 9 November 2021 from:
 - [Our World in Data](#) for all countries (aside from Australia, Japan, and Singapore)⁷
 - [COVID LIVE](#) for Australia, which verifies data against Australian state and territory government health departments¹³
 - [Singapore Ministry of Health](#) for Singapore¹⁴
 - [Japan Ministry of Health](#) for Japan¹⁵
 - NSW Health via the Patient Flow Portal for NSW, taken from a 7pm snapshot, 7 November 2021¹¹
 - [COVID-19 Tracker Canada](#) for Ontario and Quebec.¹²

COVID-19 cases, variants, vaccines, hospitalisations and deaths

Notes

- With regards to the figures on COVID-19 variants, all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences were downloaded from the [GISAID EpiCOV™ Database](#). PANGO lineage (variant) classification for each individual sequence was provided by GISAID.¹⁶
- Dates are based on the sample collection date. Sequences with dates specifying the year only were excluded, while collection dates specifying the year and month were assigned to the 15th of that month.
- Sequences with lengths $\leq 20,000$ base pairs were removed from the analysis, as were non-human hosts.
- Only a non-random sample of cases are sequenced. For many countries, the proportion of cases sequenced is very low. As a result, this report does not indicate the true prevalence of the variants but rather a best estimate currently available.
- All data used to generate these graphs is subject to the GISAID [terms and conditions](#).¹⁷

Sources

- Data on variants enabled by [GISAID](#); accessed 9 November 2021.¹⁶
- Data on total number of cases and vaccinations for the selected countries are sourced from [Our World in Data](#); accessed 9 November 2021.⁷
- Data on total number of cases for NSW are sourced from NSW Health via the Notifiable Conditions Information Management System.⁸ Data on vaccinations for NSW are sourced from NSW Health via the Australian Government Department of Health Australian Immunisation Register.¹⁰ All accessed 9 November 2021.
- Data on the number of hospitalisations and new deaths for the United Kingdom, the United States, Canada and Israel were sourced from [Our World in Data](#).^{7, 13} Data on the number of hospitalisations and new deaths for Australia were sourced from [COVID LIVE](#), which verifies data against Australian state and territory government health departments.¹³ Data on the number of hospitalisations for NSW were sourced from NSW Health via the Patient Flow Portal.¹¹ Data on the number of deaths for NSW are sourced from NSW Health via the Notifiable Conditions Information Management System.⁸ All accessed 9 November 2021.

Method

The NSW Health Critical Intelligence Unit maintains living evidence tables on [COVID-19 vaccines](#) and [SARS-CoV-2 variants](#).^{18, 19} To inform this brief, a review of the daily evidence digest and Google searches were undertaken on 8 November 2021.

Countries were chosen based on contemporary relevance with regards to the variables of interest in the NSW and Australian context (cases, variants, vaccines and patient outcomes).

References

1. Iacobucci G. Covid-19: How is the UK's vaccine booster programme faring? *BMJ*. 2021;375:n2702. DOI: 10.1136/bmj.n2702
2. Tanne JH. Covid-19: US doctors begin administering vaccine to children aged 5-11. *BMJ*. 2021;375:n2693. DOI: 10.1136/bmj.n2693
3. The Guardian. Scott Morrison says WA border policy doing 'more harm than good' – as it happened [Internet]. Australia: The Guardian; 8 November 2021 [cited 8 November 2021]. Available from: <https://www.theguardian.com/australia-news/live/2021/nov/08/australia-news-live-update-covid-booster-nsw-pfizer-victoria-morrison-vaccination->
4. ABC News. Europe's COVID-19 surge a 'grave concern' says WHO, as hospitalisations double in one week [Internet]. Australia: ABC News; 5 November 2021 [cited 8 November 2021]. Available from: <https://www.abc.net.au/news/2021-11-05/europe-grave-concern-500k-covid-deaths-surge/100596398>.
5. ABC News. What are Ronapreve and PF-07321332, the two new COVID-19 treatments Australia has gained access to? [Internet]. Australia: ABC News; 17 October 2021 [cited 8 November 2021]. Available from: <https://www.abc.net.au/news/2021-10-17/what-are-new-covid-19-treatments-ronapreve-pf-07321332/100545708>.
6. Pfizer. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 epic-hr study [Internet]. United States: Pfizer; 5 November 2021 [cited 8 November 2021]. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate>.
7. Our World in Data. Latest publication [Internet]. United Kingdom: Our World in Data; 1 June 2021 [cited 14 September 2021]. Available from: <https://ourworldindata.org/>.
8. NSW Ministry of Health. Notifiable Conditions Information Management System (NCIMS) [unpublished dataset]. Sydney: NSW Ministry of Health; 2021 [cited 14 September 2021].
9. NSW Department of Planning, Industry and Environment. Population [Internet]. Australia: NSW Department of Planning, Industry and Environment; 2020 [cited 29 September 2021]. Available from: <https://www.planning.nsw.gov.au/Research-and-Demography/Population-projections>.
10. Australian Government Department of Health. Australian immunisation register [unpublished dataset]. Australia: Australian Government Department of Health; 2021 [cited 14 September 2021].
11. NSW Ministry of Health. Patient flow portal [unpublished dataset]. Sydney: NSW Ministry of Health; 2021 [cited 14 September 2021].
12. COVID-19 Tracker Canada. Updated Wednesday, October 27th at 3:48 pm CST [Internet]. Canada; 27 October 2021 [cited 28 October 2021]. Available from: <https://covid19tracker.ca/index.html>.
13. COVID LIVE [Internet]. Australia: COVID LIVE; 22 September 2021 [cited 22 September 2021]. Available from: <https://covidlive.com.au/>.
14. Ministry of Health Singapore. COVID-19 Statistics [Internet] Singapore: Ministry of Health; 25 October 2021 [cited 27 October 2021] Available from: <https://www.moh.gov.sg/covid-19/statistics>.
15. Ministry of Health, Labour and Welfare. Situation report [Internet]. Japan: Ministry of Health, Labour and Welfare; 27 October 2021 [cited 28 October 2021]. Available from: https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou_00006.html.
16. GISAID. In focus [Internet]. Germany: GISAID; 2021. [cited 14 September 2021]. Available from: <https://www.gisaid.org/>.
17. GISAID. GISAID EpiFlu™ Database Access Agreement [Internet]. Germany: GISAID; 2021 [cited 14 September 2021]. Available from: <https://www.gisaid.org/registration/terms-of-use/>.
18. COVID-19 Critical Intelligence Unit. Living evidence - SARS-CoV-2 variants [Internet]. Sydney: NSW Agency for Clinical Innovation; September 2021 [cited 14 September 2021]. Available from: <https://aci.health.nsw.gov.au/covid-19/critical-intelligence-unit/sars-cov-2-variants>.

19. COVID-19 Critical Intelligence Unit. Living evidence - COVID-19 vaccines [Internet]. Sydney, Australia: NSW Agency for Clinical Innovation; 2021 [cited 14 September 2021]. Available from: <https://aci.health.nsw.gov.au/covid-19/critical-intelligence-unit/covid-19-vaccines>.

SHPN: (ACI) 211009 | ISBN: 978-1-76081-998-9 | TRIM: ACI/D21/856-28